503 related articles for article (PubMed ID: 18485128)
1. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
Calabrese C; Liguori G; Gabusi V; Gionchetti P; Rizzello F; Straforini G; Brugnera R; Di Febo G
Aliment Pharmacol Ther; 2008 Jul; 28(2):250-5. PubMed ID: 18485128
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
Castell D; Bagin R; Goldlust B; Major J; Hepburn B
Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
[TBL] [Abstract][Full Text] [Related]
3. Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy.
Garrean CP; Zhang Q; Gonsalves N; Hirano I
Am J Gastroenterol; 2008 Jul; 103(7):1631-7. PubMed ID: 18557714
[TBL] [Abstract][Full Text] [Related]
4. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
Howden CW; Ballard ED; Koch FK; Gautille TC; Bagin RG
J Clin Gastroenterol; 2009 Apr; 43(4):323-6. PubMed ID: 18758373
[TBL] [Abstract][Full Text] [Related]
5. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
Bautista J; Fullerton H; Briseno M; Cui H; Fass R
Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
[TBL] [Abstract][Full Text] [Related]
7. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
8. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.
Frazzoni M; De Micheli E; Grisendi A; Savarino V
Aliment Pharmacol Ther; 2002 Jan; 16(1):35-9. PubMed ID: 11856076
[TBL] [Abstract][Full Text] [Related]
9. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Bytzer P; van Zanten SV; Mattsson H; Wernersson B
Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
[TBL] [Abstract][Full Text] [Related]
10. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
11. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
Newton M; Burnham WR; Kamm MA
Eur J Gastroenterol Hepatol; 1998 Sep; 10(9):753-8. PubMed ID: 9831269
[TBL] [Abstract][Full Text] [Related]
12. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Jaspersen D; Diehl KL; Schoeppner H; Geyer P; Martens E
Aliment Pharmacol Ther; 1998 Jan; 12(1):49-52. PubMed ID: 9692700
[TBL] [Abstract][Full Text] [Related]
13. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
[TBL] [Abstract][Full Text] [Related]
14. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
Park W; Hicks DM; Khandwala F; Richter JE; Abelson TI; Milstein C; Vaezi MF
Laryngoscope; 2005 Jul; 115(7):1230-8. PubMed ID: 15995512
[TBL] [Abstract][Full Text] [Related]
15. [Non-erosive gastroesophageal reflux disease. Incidence of clinical forms, characteristics of esophageal exposure to acid and symptomatic correlations].
Soto Pérez JC; Icaza ME; Vargas F; Valdovinos Díaz MA
Rev Gastroenterol Mex; 2003; 68(2):113-9. PubMed ID: 15127647
[TBL] [Abstract][Full Text] [Related]
16. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
Frazzoni M; De Micheli E; Grisendi A; Savarino V
Aliment Pharmacol Ther; 2003 Jan; 17(2):235-41. PubMed ID: 12534408
[TBL] [Abstract][Full Text] [Related]
17. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
Dickman R; Emmons S; Cui H; Sewell J; Hernández D; Esquivel RF; Fass R
Aliment Pharmacol Ther; 2005 Sep; 22(6):547-55. PubMed ID: 16167971
[TBL] [Abstract][Full Text] [Related]
18. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
Johnson DA; Stacy T; Ryan M; Wootton T; Willis J; Hornbuckle K; Brooks W; Doviak M
Aliment Pharmacol Ther; 2005 Jul; 22(2):129-34. PubMed ID: 16011671
[TBL] [Abstract][Full Text] [Related]
19. Impact of pantoprazole on duodeno-gastro-esophageal reflux (DGER).
Kunsch S; Neesse A; Linhart T; Steinkamp M; Fensterer H; Adler G; Gress TM; Ellenrieder V
Z Gastroenterol; 2009 Mar; 47(3):277-82. PubMed ID: 19280541
[TBL] [Abstract][Full Text] [Related]
20. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus.
Gerson LB; Shetler K; Triadafilopoulos G
Dig Liver Dis; 2005 Sep; 37(9):651-8. PubMed ID: 15919250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
